Last reviewed · How we verify
NCT04569903
Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records
EARLY_PHASE1 trial testing Computer algorithm for ATTR in Transthyretin Amyloidosis. Withdrawn.
1 February 2025
Quick facts
| Lead sponsor | Yale University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Start date | 1 August 2022 |
| Primary completion | 1 February 2025 |
| Estimated completion | 1 February 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Computer algorithm for ATTR
Conditions studied
- Transthyretin Amyloidosis — all drugs for Transthyretin Amyloidosis →
Sponsor
Yale University
Who can join
18 and older, any sex, with Transthyretin Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to evaluate the diagnostic performance of an algorithm in identifying patients with ATTR amyloidosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04569903
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transthyretin Amyloidosis
Currently open trials in the same condition.
- NCT07205666 — The Eplontersen Pregnancy and Lactation Outcomes Study · recruiting
- NCT06465810 — Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis · recruiting
- NCT06345235 — New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis · recruiting
- NCT05758493 — Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis · Phase 2 · recruiting
- NCT05023889 — Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy · EARLY_PHASE1 · active not recruiting
Other Yale University trials
Trials by the same sponsor.
- NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
- NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
- NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
- NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
- NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04569903 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yale University
- Last refreshed: 18 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04569903.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing